Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Psych Atlanta PC

Neither a doctor nor a teaching hospital

Research payments

$1,433,248

311 payments

Through program year 2025, Psych Atlanta PC is reported as receiving $1,433,248 in research payments, across 311 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $74,697 64
2024 Research $105,010 50
2023 Research $346,143 82
2022 Research $242,580 39
2021 Research $314,634 50
2020 Research $315,411 20
2019 Research $34,772 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. LivaNova USA, Inc. $576,708 186 payments
  2. Teva Pharmaceuticals USA, Inc. $411,204 35 payments
  3. Janssen Research & Development, LLC $238,033 30 payments
  4. Sumitomo Pharma America, Inc. $81,037 26 payments
  5. Sage Therapeutics, Inc. $59,516 2 payments
  6. Neurocrine Biosciences, Inc. $40,093 25 payments
  7. AbbVie, Inc. $18,935 3 payments
  8. Sunovion Pharmaceuticals Inc. $4,470 1 payment
  9. Supernus Pharmaceuticals, Inc. $2,635 2 payments
  10. H. Lundbeck A S $617 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $322,942 15 payments
  2. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $320,193 54 payments
  3. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $238,033 30 payments
  4. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $121,063 27 payments
  5. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $88,262 20 payments
  6. Recover $84,753 99 payments
  7. A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. $68,890 21 payments
  8. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $59,516 2 payments
  9. The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes $50,699 6 payments
  10. A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia $40,093 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record